Insider Transactions in Q3 2025 at Catalyst Pharmaceuticals, Inc. (CPRX)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Open market or private sale
|
Direct |
30,000
-9.97%
|
$600,000
$20.3 P/Share
|
|
Sep 08
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
112,475
+27.2%
|
$224,950
$2.24 P/Share
|
|
Sep 04
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Open market or private sale
|
Direct |
30,000
-13.73%
|
$570,000
$19.52 P/Share
|
|
Sep 04
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+12.07%
|
$60,000
$2.24 P/Share
|
|
Sep 03
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Open market or private sale
|
Direct |
20,000
-9.59%
|
$400,000
$20.08 P/Share
|
|
Sep 03
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+8.75%
|
$40,000
$2.24 P/Share
|
|
Aug 27
2025
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110,000
+9.4%
|
$220,000
$2.24 P/Share
|
|
Aug 27
2025
|
David S Tierney Director |
SELL
Open market or private sale
|
Direct |
26,000
-6.41%
|
$520,000
$20.2 P/Share
|
|
Aug 27
2025
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+10.97%
|
$100,000
$2.24 P/Share
|
|
Aug 26
2025
|
Richard J Daly President and CEO |
SELL
Open market or private sale
|
Direct |
22,970
-9.2%
|
$459,400
$20.62 P/Share
|
|
Aug 26
2025
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+16.68%
|
$100,000
$2.24 P/Share
|
|
Aug 26
2025
|
Steve Miller Chief Op. & Scientific Officer |
SELL
Open market or private sale
|
Direct |
115,000
-10.8%
|
$2,300,000
$20.28 P/Share
|
|
Aug 26
2025
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
115,000
+9.75%
|
$230,000
$2.24 P/Share
|